RevMed's Pancreatic Cancer Pill Priced Above $475K per Year
BloombergDuration: 10:08
Read the full storyUp next
- Agilent CEO on 3Q Earnings, Life Sciences Outlook
- Everpure CEO on Earnings, AI Hyperscaler Impact
- Software Stocks Will Rebound From the Ashes, Malik Says
- Investors Looking For Rate Clarity From Warsh Likely Disappointed, Says Jack Manley
- Nvidia Fuels a Tech-Led Rally as Market Breadth Narrows | Closing Bell
- Rates At This Level Are Reasonably Priced: Wise
